Telmisartan is angiotensin II receptor blocker (ARB) prescribed for treatment of hypertension and management of cardiovascular risk. It is effective in controlling hypertension and is well tolerated. It is used as monotherapy or can be combined with other antihypertensive drugs. Telmisartan maintains plasma electrolyte balance and has mild side effects.

The global Telmisartan Market is estimated to be valued at US$ 4109.53 Bn in 2023 and is expected to exhibit a CAGR of 5.2% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The prevalence of cardiovascular diseases around the world has been steadily rising over the past few decades. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death and disability globally. Hypertension or high blood pressure is a major risk factor for heart attacks, strokes and kidney diseases. Growing geriatric population and increasing lifestyle diseases have contributed significantly to the rising prevalence of high blood pressure worldwide. Growing awareness regarding management of hypertension to prevent cardiovascular complications has augmented the demand for effective antihypertensive drugs like telmisartan globally. Advancements in drug delivery systems are also helping improve patient compliance and driving the growth of telmisartan market during the forecast period.

Segment Analysis
The global telmisartan market is dominated by the 40 mg sub-segment. This is because 40 mg is the most common prescribed dosage for hypertension or heart disease patients. As per medical guidelines, 40 mg is recommended as the initial dosage which can later be increased to 80 mg based on patient's condition and response to treatment. Since hypertension and cardiovascular diseases are highly prevalent, the 40 mg sub-segment accounts for over 35% of the global telmisartan market.

Key Takeaways
The Global Telmisartan Market Demand is expected to witness high growth over the forecast period of 2024 to 2031. The global Telmisartan Market is estimated to be valued at US$ 4109.53 Bn in 2023 and is expected to exhibit a CAGR of 5.2% over the forecast period 2024 to 2031.

Regional analysis: Asia Pacific region currently dominates the global telmisartan market with over 40% share. This is because countries like China and India have a huge population suffering from hypertension. Also, growing geriatric population prone to heart diseases is driving the market in Asia Pacific. North America is another major region for telmisartan market owing to rising awareness about treatment and management of blood pressure.

Key players: Key players operating in the telmisartan market are Global Self Storage Inc., U-Haul International Inc. (Amerco), Urban Self Storage Inc., Life Storage Inc., Amsdell Cos./Compass Self Storage, CubeSmart LP, All Storage, National Storage Affiliates Trust, National Storage REIT, Safestore Holdings PLC, (Great Value Storage) World Class Capital Group LLC, Simply Self Storage Management LLC, SmartStop Asset Management LLC, StorageMart, Metro Storage LLC, Prime Storage Group, and W. P. Carey Inc.

For more details on the report, Read-